Related Experiment Video
Updated: Jun 6, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Treatment of paroxysmal dyskinesias
Adam Strzelczyk1, Katrin Bürk, Wolfgang H Oertel
1Philipps-University Marburg, Department of Neurology and Interdisciplinary Epilepsy Center, Rudolf-Bultmann-Str. 8, 35039 Marburg, Germany. adam.strzelczyk@med.uni-marburg.de
Importance Of The Field:
Paroxysmal dyskinesias represent a heterogeneous group of rare diseases sharing characteristics with two important groups of neurological disorders, the movement disorders and the epilepsies. Their common hallmark is the paroxysmal occurrence of dyskinesias including athetosis, ballism, chorea and dystonia. During the last two decades, various genetic abnormalities have been identified thereby providing insight into the underlying pathophysiology and offering therapeutic opportunities for many of these conditions.
Areas Covered In This Review:
We summarize the diagnostic criteria of idiopathic and symptomatic paroxysmal dyskinesias and describe their therapeutic options. For the preparation of this review article, an extensive literature search was undertaken using PubMed.
What The Reader Will Gain:
This review provides a practical guide to the diagnosis and treatment of paroxysmal dyskinesias.
Take Home Message:
The mainstay of therapy is carbamazepine for paroxysmal kinesigenic dyskinesias and clonazepam for the nonkinesigenic dyskinesias. In symptomatic paroxysmal dyskinesias, the treatment of the underlying disease will provide best results. The ketogenic diet for patients with paroxysmal exertion-induced dyskinesias is a promising new therapeutic strategy and may not only prevent attacks but also lead to improvement of developmental delay in affected children.
More Related Videos
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Depolarizing Blockers: Pharmocokinetics
Skeletal Muscle Relaxants: Therapeutic Uses
Parkinson's Disease: Overview
Dysrhythmias VI: Management of Dysrhythmias